Kinnate Biopharma Inc.

KNTENASDAQHealthcare

$2.65

$-0.01(-0.38%)

Market Cap$124990960

P/E Ratio—

52W High$7.185

52W Low$1.04

Avg Volume418K

Open$2.65

Beta1.34

Insider Trades Ownership Employees

Kinnate Biopharma Inc. (KNTE) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · KNTE · as of Jun 9, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

NEUTRAL

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

Kinnate Biopharma Inc. insiders have shown mixed buying and selling activity over the past 12 Months.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

KNTE insider buying and selling by quarter

KNTE insider selling · KNTE insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

8.9M4.5M0

2022 Q3

2022 Q4

2023 Q1

2023 Q2

2023 Q3

2023 Q4

2024 Q1

2024 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Recent insider transactions

KNTE executive sell shares · KNTE board member insider trading · KNTE insider trading SEC filing

Showing 50 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Apr 3, 2024	Tananbaum James B. Director	Other	520,711	$2.59	$1.35M⚡	0	Form 4
Apr 3, 2024	Farzan Nima CHIEF EXECUTIVE OFFICER · Director	Other	2,186	$2.59	$6K	0	Form 4
Apr 3, 2024	Krishnamohan Neha CHIEF FINANCIAL OFFICER	Other	64,087	$2.59	$166K	0	Form 4
Apr 3, 2024	Flaherty Keith T. Director	Other	66,377	$2.59	$172K	0	Form 4
Apr 3, 2024	Meltz Mark A COO GENERAL COUNSEL SECRETARY	Other	27,578	$2.59	$71K	0	Form 4
Apr 3, 2024	GORDON CARL L Director	Other	450,000	$2.59	$1.16M⚡	0	Form 4
Apr 3, 2024	ORBIMED ADVISORS LLC Director	Other	450,000	$2.59	$1.16M⚡	0	Form 4
Apr 3, 2024	Foresite Capital Management IV, LLC 10 percent owner	Other	520,711	$2.59	$1.35M⚡	0	Form 4
Mar 1, 2024	Krishnamohan Neha CHIEF FINANCIAL OFFICER	Other	1,506	$2.59	$4K	64,087	Form 4
Mar 1, 2024	Meltz Mark A COO GENERAL COUNSEL SECRETARY	Other	558	$2.59	$1K	27,578	Form 4
Mar 1, 2024	Williams Richard Thomas CHIEF MEDICAL OFFICER	Other	558	$2.59	$1K	67,588	Form 4
Dec 1, 2023	Williams Richard Thomas Chief Medical Officer	Other	541	$2.25	$1K	68,146	Form 4
Dec 1, 2023	Krishnamohan Neha CFO	Other	1,459	$2.25	$3K	65,593	Form 4
Dec 1, 2023	Meltz Mark A COO General Counsel Secretary	Other	541	$2.25	$1K	28,136	Form 4
Sep 1, 2023	Krishnamohan Neha CFO	Other	1,459	$2.35	$3K	67,052	Form 4
Sep 1, 2023	Meltz Mark A COO General Counsel Secretary	Other	541	$2.35	$1K	28,677	Form 4
Sep 1, 2023	Williams Richard Thomas Chief Medical Officer	Other	541	$2.35	$1K	68,687	Form 4
Jun 1, 2023	Williams Richard Thomas Chief Medical Officer	Other	541	$4.30	$2K	69,228	Form 4
Jun 1, 2023	Meltz Mark A COO General Counsel Secretary	Other	541	$4.30	$2K	29,218	Form 4
Jun 1, 2023	Krishnamohan Neha CFO	Other	1,459	$4.30	$6K	68,511	Form 4
May 8, 2023	Tananbaum James B. Director	Purchase	1,550,956	$2.80	$4.34M⚡	3,525,957	Form 4
May 8, 2023	Tananbaum James B. Director	Purchase	229,044	$2.80	$641K	520,711	Form 4
May 8, 2023	Foresite Capital Management IV, LLC 10 percent owner	Purchase	1,550,956	$2.80	$4.34M⚡	3,525,957	Form 4
May 8, 2023	Foresite Capital Management IV, LLC 10 percent owner	Purchase	229,044	$2.80	$641K	520,711	Form 4
May 4, 2023	ORBIMED ADVISORS LLC Director	Purchase	312,991	$2.75	$861K	4,738,453	Form 4

Tananbaum James B.

Director

Other

Date

Apr 3

520,711

Price

$2.59

Value

$1.35M ⚡

View Form 4 on SEC.gov

Farzan Nima

CHIEF EXECUTIVE OFFICER · Director

Other

Date

Apr 3

2,186

Price

$2.59

Value

$6K

View Form 4 on SEC.gov

Krishnamohan Neha

CHIEF FINANCIAL OFFICER

Other

Date

Apr 3

64,087

Price

$2.59

Value

$166K

View Form 4 on SEC.gov

Flaherty Keith T.

Director

Other

Date

Apr 3

66,377

Price

$2.59

Value

$172K

View Form 4 on SEC.gov

Meltz Mark A

COO GENERAL COUNSEL SECRETARY

Other

Date

Apr 3

27,578

Price

$2.59

Value

$71K

View Form 4 on SEC.gov

GORDON CARL L

Director

Other

Date

Apr 3

450,000

Price

$2.59

Value

$1.16M ⚡

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

Director

Other

Date

Apr 3

450,000

Price

$2.59

Value

$1.16M ⚡

View Form 4 on SEC.gov

Foresite Capital Management IV, LLC

10 percent owner

Other

Date

Apr 3

520,711

Price

$2.59

Value

$1.35M ⚡

View Form 4 on SEC.gov

Krishnamohan Neha

CHIEF FINANCIAL OFFICER

Other

Date

Mar 1

1,506

Price

$2.59

Value

$4K

View Form 4 on SEC.gov

Meltz Mark A

COO GENERAL COUNSEL SECRETARY

Other

Date

Mar 1

558

Price

$2.59

Value

$1K

View Form 4 on SEC.gov

Williams Richard Thomas

CHIEF MEDICAL OFFICER

Other

Date

Mar 1

558

Price

$2.59

Value

$1K

View Form 4 on SEC.gov

Williams Richard Thomas

Chief Medical Officer

Other

Date

Dec 1

541

Price

$2.25

Value

$1K

View Form 4 on SEC.gov

Krishnamohan Neha

CFO

Other

Date

Dec 1

1,459

Price

$2.25

Value

$3K

View Form 4 on SEC.gov

Meltz Mark A

COO General Counsel Secretary

Other

Date

Dec 1

541

Price

$2.25

Value

$1K

View Form 4 on SEC.gov

Krishnamohan Neha

CFO

Other

Date

Sep 1

1,459

Price

$2.35

Value

$3K

View Form 4 on SEC.gov

Meltz Mark A

COO General Counsel Secretary

Other

Date

Sep 1

541

Price

$2.35

Value

$1K

View Form 4 on SEC.gov

Williams Richard Thomas

Chief Medical Officer

Other

Date

Sep 1

541

Price

$2.35

Value

$1K

View Form 4 on SEC.gov

Williams Richard Thomas

Chief Medical Officer

Other

Date

Jun 1

541

Price

$4.30

Value

$2K

View Form 4 on SEC.gov

Meltz Mark A

COO General Counsel Secretary

Other

Date

Jun 1

541

Price

$4.30

Value

$2K

View Form 4 on SEC.gov

Krishnamohan Neha

CFO

Other

Date

Jun 1

1,459

Price

$4.30

Value

$6K

View Form 4 on SEC.gov

Tananbaum James B.

Director

Purchase

Date

May 8

1,550,956

Price

$2.80

Value

$4.34M ⚡

View Form 4 on SEC.gov

Tananbaum James B.

Director

Purchase

Date

May 8

229,044

Price

$2.80

Value

$641K

View Form 4 on SEC.gov

Foresite Capital Management IV, LLC

10 percent owner

Purchase

Date

May 8

1,550,956

Price

$2.80

Value

$4.34M ⚡

View Form 4 on SEC.gov

Foresite Capital Management IV, LLC

10 percent owner

Purchase

Date

May 8

229,044

Price

$2.80

Value

$641K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

Director

Purchase

Date

May 4

312,991

Price

$2.75

Value

$861K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 2

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About KNTE insider trading

KNTE insider trades

Kinnate Biopharma Inc. (KNTE) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including KNTE. Over the past 12 months, 0 insiders have filed transactions with the SEC. KNTE insiders have been mixed buying and selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Kinnate Biopharma Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

KNTE insider trading · 5 questions

The insiders of Kinnate Biopharma Inc. (KNTE) include executives and directors such as KNTE, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

KNTE board member insider tradingwho are KNTE insidersKNTE insider rosterKinnate Biopharma Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026